ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

MLA

Juan Carlos Tercero, et al. ERCC5/XPG, ERCC1, and BRCA1 Gene Status and Clinical Benefit of Trabectedin in Patients with Soft Tissue Sarcoma. Aug. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....42cb82e8f36bcaf4e780c7581c4c6ea6&authtype=sso&custid=ns315887.

APA

Juan Carlos Tercero, Roberta Sanfilippo, Isabelle Ray-Coquard, Antoine Italiano, Audrey Laroche, Jean-Yves Blay, Armelle Laurand, Axel Le Cesne, Binh Bui, Jean Michel Coindre, Paolo G. Casali, Jacques Robert, Ian Judson, Antonio Nieto, Philippe Pourquier, & José Enrique Garzón Jimeno. (2011). ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.

Chicago

Juan Carlos Tercero, Roberta Sanfilippo, Isabelle Ray-Coquard, Antoine Italiano, Audrey Laroche, Jean-Yves Blay, Armelle Laurand, et al. 2011. “ERCC5/XPG, ERCC1, and BRCA1 Gene Status and Clinical Benefit of Trabectedin in Patients with Soft Tissue Sarcoma,” August. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....42cb82e8f36bcaf4e780c7581c4c6ea6&authtype=sso&custid=ns315887.